From the Departments of Radiology and Nuclear Medicine (P.M., C.E., M.M.L., K.D.)
Institute of Radiology (P.M., M.M.L.), Friedrich-Alexander University, University of Erlangen-Nuremberg, Erlangen, Germany.
AJNR Am J Neuroradiol. 2022 Jul;43(7):1012-1017. doi: 10.3174/ajnr.A7552. Epub 2022 Jun 30.
There is growing evidence of leakage of gadolinium in an impaired blood-retina barrier. We investigated gadolinium enhancement in different eye compartments and correlated the enhancement with specific ophthalmologic diseases.
In a prospective clinical study (ClinicalTrials.gov Identifier: NCT05035251), 95 patients (63 with and 32 without ophthalmologic disease) were examined before and after gadolinium administration (20 and 120 minutes) with heavily T2-weighted FLAIR. The cohort was divided according to the location of pathology into anterior and posterior eye compartment groups. Relative signal intensity increase in the anterior eye chamber, vitreous body with retina, optic nerve sheath, and the Meckel cave was analyzed and correlated with the final clinical diagnosis.
In patients with a disorder in the anterior eye compartment, significant signal intensity increases were found in the central anterior eye chamber ( 20 minutes = .000, 120 minutes = .000), lateral anterior eye chamber ( 20 minutes = .001, 120 minutes = .005), and vitreous body with retina ( 20 minutes = .02) compared with the control group. Patients with pathologies in the posterior eye compartment showed higher signal intensity levels in the central anterior eye compartment ( 20 minutes = .041) and vitreous body with retina ( 120 minutes = .006).
Increased gadolinium enhancement was found in the central and lateral anterior eye compartments and the vitreous body with retina in patients with anterior eye compartment disorders 20 and 120 minutes after contrast application, suggesting impairment of the blood-aqueous barrier. In patients with a disorder in the posterior eye compartment, pathologic enhancement indicated disruption of the blood-retinal barrier that allows gadolinium to diffuse into the vitreous body with retina from posterior to anterior, opposite to the known physiologic glymphatic pathway.
越来越多的证据表明,在血视网膜屏障受损的情况下,钆会发生渗漏。我们研究了不同眼部隔室的钆增强,并将增强与特定的眼科疾病相关联。
在一项前瞻性临床研究(ClinicalTrials.gov 标识符:NCT05035251)中,95 名患者(63 名患有和 32 名不患有眼科疾病)在注射钆前后(20 分钟和 120 分钟)进行了重度 T2 加权 FLAIR 检查。根据病变部位,将队列分为前眼隔室组和后眼隔室组。分析了前眼前房、玻璃体伴视网膜、视神经鞘和 Meckel 窝的相对信号强度增加,并与最终临床诊断相关联。
在前眼隔室疾病患者中,中央前眼前房(20 分钟 =.000,120 分钟 =.000)、侧眼前房(20 分钟 =.001,120 分钟 =.005)和玻璃体伴视网膜(20 分钟 =.02)的信号强度增加显著,与对照组相比。后眼隔室疾病患者的中央前眼前房(20 分钟 =.041)和玻璃体伴视网膜(120 分钟 =.006)的信号强度水平较高。
在注射造影剂后 20 分钟和 120 分钟,前眼隔室疾病患者的中央和侧前眼前房以及玻璃体伴视网膜出现了增强,提示血房水屏障受损。在后眼隔室疾病患者中,病理增强表明血视网膜屏障受损,允许钆从后向前扩散到玻璃体伴视网膜,与已知的生理神经胶质途径相反。